Orally available and long-acting prodrug of MRE 269, a potent and highly selective IP receptor agonist (Ki values 20 nM and 260 nM for inhibition of [3H]iloprost binding to human IP receptor by MRE 269 and Selexipag, respectively). Capable of ameliorating vascular endothelial dysfunction, pulmonary arterial wall hypertrophy, and right ventricular hypertrophy. Furthermore, Selexipag (NS 304) elevated right ventricular systolic pressure and improved survival in a rat model of pulmonary hypertension induced by monocrotaline (MCT).

KEYWORDS: Selexipag | supplier | IP agonist prodrug | NS 304 | ACT 293987 | NS304 | ACT293987 | CAS [475086-01-2] - [1267423-51-7] | Prostaglandins | PGI2 (IP) | Agonist | MRE269 | prodrug | prostacyclin | PGI2 | pulmonary | hypertension | vascular | endothelial | dysfunction | hypertrophy